Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays

生物制药公司Can-Fite与大麻公司univo合作,开发大麻药物

2019-09-11 08:30:58 BioSpace

本文共2163个字,阅读需6分钟

Cannabinoids bind to A3AR, the target of Can-Fite’s drugs Can-Fite’s unparalleled expertise in these targets will be utilized to develop new cannabis-based pharmaceuticals The transaction involves technology exchange, co-development, and revenue share on CBD-based pharmaceuticals and CBD-based A3AR assays Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver, and inflammatory diseases, announced today it has entered into a collaboration agreement with Univo Pharmaceuticals (TASE:UNVO), a medical cannabis company, to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It is widely recognized that the identification of specific receptors and pathways through which CBD operates is expected to greatly enhance the development of CBD-based pharmaceuticals. Can-Fite is uniquely positioned to contribute its deep pharmaceutical development expertise to the CBD market, based on findings published in peer reviewed scientific journals demonstrating that CBDs bind to the Gi protein-coupled A3 adenosine receptor (A3AR), which is over-expressed in pathological cells. Can-Fite is a global leader in the research and development of drugs that target A3AR. There are two main components to the collaboration agreement: Discovery, development, and commercialization of medical cannabis-based therapeutics: Can-Fite and Univo will jointly collaborate in the discovery of, and Can-Fite will have a first right to express interest to clinically develop, cannabis and cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Development and commercialization of CBD screening assays: Can-Fite will develop a screening assay to identify therapeutically active cannabis components, and once developed, Univo will market the assay on a ‘fee for service’ basis to other pharmaceutical companies worldwide. According to Adroit Market Research, the medical cannabis market is projected to grow at a CAGR of 29% to $56.7 billion by 2026 and according to Zion Market Research, the global market for cell-based assays is estimated to reach $16.2 billion by 2025. In this collaboration, Univo will provide Can-Fite with cannabis and cannabis components, as well as full access to its laboratories for both research and manufacturing. Can-Fite has agreed to pay Univo a total of $500,000 through two installments and is issuing to Univo approximately 19.9 million of its ordinary shares through a private placement, representing approximately 16.6% of Can-Fite’s ordinary shares outstanding after giving effect to the issuance. The companies will initially share ownership of intellectual property developed in this collaboration. Revenues derived from the collaboration will generally be shared between Can-Fite and Univo on the basis of each party’s contribution. Golan Bitton, Univo’s CEO, is being appointed to the Can-Fite board in connection with the collaboration agreement. Dr. Pnina Fishman, Can-Fite CEO, commented, “This collaboration provides Can-Fite with new and very exciting business opportunities for utilizing our technology platform and expertise.” Golan Bitton, Univo’s CEO stated, “Can-Fite’s deep expertise in A3 adenosine receptors is a significant asset in our joint collaboration and we are pleased to have formed this alliance. Can-Fite has taken its drug candidates into Phase II and Phase III clinical studies and this makes Can-Fite highly suitable to take cannabis-based therapeutics into fully-fledged clinical development.” About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date. For more information please visit: www.can-fite.com. About UNIVO Pharmaceuticals UNIVO (TASE:UNVO) is a vertically-integrated medical cannabis company including cultivation, manufacturing and distribution as well as the creation of innovative products and dosage forms for next-generation medical cannabis products. UNIVO holds initial licenses for the entire supply chain: growing, breeding and nursery, production of medical cannabis products, research and development and distribution. UNIVO plans to source its own cannabis by way of a partnership with Amit Farms, located in the South of Israel covering over 75,000m² with 15,000 m² to be designated for cannabis growth. It is intended that the farm will use state-of-the art innovative agricultural technologies to grow high quality cannabis and develop UNIVO’s own strains targeted to meet specific therapeutic needs. UNIVO’s IMC-GMP manufacturing facility plans to produce a wide variety of medical cannabis products that meet the most stringent international standards. The plant is scheduled to receive IMC-GMP certification and begin production in Q3-Q4 2019. UNIVO uses state-of-the-art ethanol and CO2 based extraction technologies to manufacture a wide range medical cannabis products. UNIVO believes its world class R&D guarantees a steady flow of new products in multiple doses with cutting edge dosage forms. The UNIVO manufacturing facility is designed to safely store all finished products according to the strictest regulatory and security requirements.
大麻素与a3ar结合,是康菲药物的靶点 能否利用菲特在这些目标方面的无与伦比的专业知识来开发新的大麻药物? 交易涉及基于CBD的药品和基于CBD的A3AR分析的技术交换、共同开发和收入份额 Can-Fite生物制药有限公司(纽约证券交易所美国:CANF)(TASE:CFBI),一家生物技术公司,拥有一系列与A3腺苷受体(A3AR)特异性结合的专利小分子药物,用于治疗癌症、肝脏和炎症疾病,宣布今天,该公司与大麻医药公司Univo Pharmaceuticals(TASE:UNVO)签订了一项合作协议,以确定和共同开发大麻成分的特定配方,用于治疗癌症、炎症、自身免疫和代谢性疾病。 人们普遍认为,确定cbd运作的特定受体和途径有望大大促进cbd药物的发展。根据发表在同行评议的科学期刊上的研究结果,Can-Fite具有独特的地位,能够为CBD市场贡献其深入的药物开发专业知识,该研究表明CBD与GI蛋白偶联的A3腺苷受体(A3AR)结合,后者在病理学上过度表达。L细胞。在针对a3ar的药物研发方面,can-fite处于全球领先地位。 合作协议有两个主要组成部分: 大麻药物疗法的发现、开发和商业化:Can-Fite和Univo将共同合作发现大麻和大麻成分,Can-Fite将首先有权表示对临床开发大麻和大麻成分治疗癌症、炎症的兴趣。肿瘤性、自身免疫性和代谢性疾病。 CBD筛选分析的开发和商业化:Can Fite将开发一种筛选分析,以识别治疗活性大麻成分,一旦开发,Univo将在“服务收费”的基础上向全球其他制药公司销售该分析。 根据adroit market research的预测,到2026年,医用大麻市场的复合年增长率将达到29%,达到567亿美元;根据zion market research的预测,到2025年,全球细胞分析市场预计将达到162亿美元。 在这一合作中,联合国毒品和犯罪问题研究所将提供大麻和大麻成分,并为研究和制造提供充分进入其实验室的机会。Can Fite已同意分两期向Univo支付总计500000美元,并通过私募向Univo发行约1990万股普通股,约占Can Fite发行生效后已发行普通股的16.6%。这些公司最初将分享在这次合作中开发的知识产权的所有权。合作产生的收入通常将由Can Fite和Univo根据各方的贡献进行分享。Univo首席执行官戈兰•比顿(Golan Bitton)正被任命为与合作协议相关的Can-Fite董事会成员。 can-fite首席执行官pnina fishman博士评论道:“这一合作为can-fite利用我们的技术平台和专业知识提供了新的、非常令人兴奋的商业机会。” Univo首席执行官戈兰•比顿(戈兰•比顿)表示:“Can-Fite在A3腺苷受体方面的深厚专业知识是我们共同合作的重要资产,我们很高兴组建了这一联盟。Can-Fite已将其候选药物纳入二期和三期临床研究,这使得Can-Fite非常适合将大麻类疗法纳入成熟的临床开发。” 关于康菲生物制药有限公司。 can-fite生物制药有限公司(纽约证券交易所美国:canf)(tase:cfbi)是一家先进的临床阶段药物开发公司,其平台技术旨在解决癌症、炎症疾病和性功能障碍治疗方面数十亿美元的市场。该公司的主要候选药物piclidenoson目前正在进行类风湿关节炎和银屑病的iii期试验。Can-Fite的肝癌药物Namodenoson最近完成了一项肝癌(HCC)的II期试验,这是最常见的肝癌形式,目前正在进行非酒精性脂肪性肝炎(NASH)的II期试验。NAMODENOSON已被美国和欧洲授予孤儿药称号,并被美国食品和药物管理局授予肝癌二线治疗快速通道称号。纳莫地诺森还证明了其治疗其他癌症的潜在概念,包括结肠癌、前列腺癌和黑色素瘤。cf602是该公司的第三个候选药物,在临床前研究中已经显示了治疗勃起功能障碍的疗效,该公司正在研究针对a3ar的其他化合物,用于治疗性功能障碍。这些药物具有良好的安全性,迄今为止已有1000多名临床研究患者的经验。更多信息请访问:www.can-fite.com。 关于Univo制药公司 univo(tase:unvo)是一家纵向一体化的医用大麻公司,包括种植、制造和分销以及为下一代医用大麻产品创造创新产品和剂型。univo拥有整个供应链的初始许可证:种植、育种和苗圃、医用大麻产品的生产、研发和分销。联沃计划通过与非盟驻以色列特派团农场的伙伴关系来采购自己的大麻,该农场位于以色列南部,占地面积超过75000平方米,其中15000平方米将用于大麻种植。该农场将利用最先进的创新农业技术种植高质量大麻,并开发Univo自己的菌株,以满足特定的治疗需要。univo的imc-gmp生产设施计划生产多种符合最严格国际标准的医用大麻产品。工厂计划获得IMC-GMP认证,并于2019年第3-4季度开始生产。univo使用最先进的乙醇和二氧化碳提取技术生产广泛的医用大麻产品。univo相信其世界级的研发保证了新产品的稳定流动,包括多种剂量的尖端剂型。Univo制造厂的设计是根据最严格的监管和安全要求安全储存所有成品。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文